The use of in-line analytics for monitoring and understanding biological processes has been promoted since 2004 through the Process Analytical Technology (PAT) initiative. Two such technologies are Raman and dielectric spectroscopies that are well established but deployed independently. For the very first time, simultaneous usage of in-line Raman and dielectric spectroscopic analytics for tracking progress of a lycopene overproducer E. coli 322 engineered strain was studied herein, alongside scale-up experimentation from shake flask to 0.5L and 10L bioreactor cultures. An intracellular lycopene extraction protocol was optimised for off-line quantification by Raman or UV-Vis spectroscopies, which aids the estimation of lycopene over-production in a high cell density E. coli fed-batch culture via in-line Raman. Correlating dielectric capacitance recordings and flow cytometry viable cell count measurements allows for real-time cell culture viability monitoring, which is more informative for bioprocess dynamic control in contrast to conventional in-/off-line biomass optical density (OD) or dry cell weight (g). This enabled fed-batch culture revitalisation prior to inducing intracellular lycopene production. The final biomass OD was ca. 81.8 corresponding to in-line dielectric capacitance estimated culture viability 43.38 g/L. Intracellular lycopene yield was estimated at 495.1 mg/g via in-line Raman, which was 12.3 times increase compared to initial trial reported for E. coli 322. The successful implementation of dual in-line dielectric capacitance and Raman monitoring exemplifies the quality by design (QbD) approach espoused by PAT framework for expediting bioprocess understanding, development and scale-up of engineered microbial strains.
No takes yet. Share an insight, caveat, or question.
Eka et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: